Adapt Or Die: Sanofi CSO On R&D Challenges Within Unstable Industry

Sanofi's chief scientific officer Gary Nabel, who joined the company in 2012 from the NIH, discusses R&D challenges for Sanofi and the wider pharma industry, and highlights the company's biggest drug development achievements and toughest moments over the last few years.

Gary Nabel
Gary Nabel, SVP and chief scientific officer at Sanofi • Source: Sanofi

More from Leadership

More from Scrip